Engaging community pharmacists in a shared care model for breast cancer survivors

Learning objectives:

- Define cancer survivorship and the underlying principles.
- Discuss the roles community pharmacists can play in breast cancer survivorship.
- Describe strategies to optimize community pharmacists' role in a multidisciplinary care team for cancer survivors.
- Discuss the types of resources commonly used to guide the implementation of health services involving pharmacists.


Ke Yu, PhD, BSc Pharm (Hons)

4 March 2023


Conflict of Disclosure

• Nothing to disclose.

Breast Cancer Burden



Cancer survivorship begins from diagnosis till the end of life



Provide treatment and manage acute toxicities in the tertiary setting

- 1. Cheung et al. Support Care Cancer. 2013;21(8):2185-94
- 2. Mahendran et al. Singap Med J. 2020
- 3. Kenyon et al. J Obstet Gynecol Neonatal Nurs. 2014;43(3):382-9

Maintaining health and maximizing quality of life in the community

Core components of survivorship care

Involvement of primary care providers is indispensable.



Health promotion Chronic conditions management

0



Care coordination between specialists and primary care providers



Monitor and manage physical, psychosocial, and practical problems

- Recurrent cancer surveillance
- Prevent and detect new cancers

1. Hewitt et al. National Academies. 2006

2. Nekhlyudov et al. J Natl Cancer Inst. 2019;111(11):1120-30

How is survivorship care delivered globally?

Care Delivery	Total (N= 27)	Total (%)	Total LIC/LMIC (n = 7)	LIC/LMIC (%)	Total UMIC (n = 7)	UMIC (%)	Total HIC (n = 13)	HIC (%)
Health care coverage								
Universal	11	40.8	0	0	2	28.6	9	69.2
Mixed system, all survivors have coverage	4	14.8	1	14.3	1	14.3	2	15.4
Mixed system, most survivors have coverage	4	14.8	1	14.3	1	14.3	2	15.4
Mixed, many survivors do not have coverage	8	29.6	5	71.4	3	42.9	0	0
Cancer-related follow-up care								
Treating institution	20	74.1	5	71.4	5	71.4	10	76.9
Mix of treating institution and GP/PCP	6	22.2	1	14.3	2	28.6	3	23.1
Most seen by GP/PCP	1	3.7	1	14.3	0	0	0	0
Many survivors receive no formal follow-up care	0	0	0	0	0	0	0	0
Noncancer-related follow-up care								
Treating institution	3	11.1	1	14.3	2	28.6	0	0
Mix treating institution and GP/PCP	8	29.6	2	28.6	1	14.3	5	38.5
Most seen by GP/PCP	13	48.1	4	57.1	2	28.6	7	53.8
Many survivors receive no formal follow-up care	3	11.1	0	0	2	28.6	1	7.7
Models of follow-up care (check all)								
Oncology	24	88.9	5	71.4	6	85.7	13	100
Primary care led	8	29.6	2	28.6	1	14.3	5	38.5
Shared care	12	44.4	3	42.9	2	28.6	7	53.8
Nurse led	5	18.5	1	14.3	0	0	4	30.8
Multidisciplinary survivorship clinic	6	22.2	2	28.6	0	0	4	30.8
None	1	3.7	0	0	1	14.3	0	0
Use of survivorship guideline								
Almost all/most	15	55.5	3	42.8	4	57.1	8	31.5
About half	6	22.2	0	0	2	28.6	4	30.8
Some	3	11.1	3	42.9	0	0	0	0
Just a few	3	11.1	1	14.3	1	14.3	1	7.7


Cancer-related care is almost <u>exclusively</u> provided by cancer centers/ hospitals	
Tertiary care providers are still consulted for non-cancer-related issues.	

Most countries adopt <u>oncologist-led</u> model, followed by <u>shared care</u> model.

Care fragmentation?

Sustainability?

Types of cancer survivorship care models



No demonstrated superiority of any care model in healthcare outcomes.

- 1. Termuhlen et al. Springer International Publishing, Cham. 2018; pp103-117
- 2. Nekhlyudov et al. Lancet Oncol. 2017; 18(1):e30-e38
- 3. Chan et al. J Cancer Surviv. 2021;1-25


Which care model should be adopted?



A <u>one-size-fits-all</u> model applicable to all survivors across all survivorship phases does not exist.

- 1. Termuhlen et al. Springer International Publishing, Cham. 2018; pp103-117
- 2. Nekhlyudov et al. Lancet Oncol. 2017; 18(1):e30-e38
- 3. Chan et al. J Cancer Surviv. 2021;1-25

A personalized approach to cancer survivorship






The development and evaluation of care models need to be <u>context-specific</u>, taking into consideration organizational and healthcare system-level factors.

- 1. Fitch MI. Can Oncol Nurs J. 2008;18(1):6-24
- 2. Vardy et al. Aust J Gen Pract 2019; 48(12):833

Community pharmacists can play a role in shared care and primary care-based models



Cancer screening advice, cancer surveillance



Egbewande et al. Innov Pharm. 2022;13(3):10.24926/iip.v13i3.4946
 Rubio-Valera et al. Int J Environ Res Public Health. 2014;11(10):10967-90

Community pharmacists' strengths are compatible with survivorship care provision

- Medication reconciliation and optimization
- Non-pharmacological counselling, lifestyle advice
- Survivorship care plans
- Communication with oncology team/ other HCPs

- Assess and manage physical toxicities
- Psychosocial support, resource provision

Promote adherence to annual surveillance mammogram and second cancer screening





- Care coordination between specialists and primary care providers Monitor and manage physical, psychosocial, and practical problems
- **Recurrent cancer** surveillance
- **Prevent and detect new**



Health promotion **Chronic conditions**

management



However, research on community pharmacists' engagement in survivorship care is limited

Specific to adjuvant treatment

The Role of Community Pharmacists in Addressing <u>Medication-related Issues</u> for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy

KINAN MOKBEL 1,2 and KEFAH MOKBEL 2

Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach

Mauranne Labonté^{a,b,c,d}, Laurence Guillaumie^{b,e}, Anne Dionne^{a,c,f}, Michel Dorval^{a,c,d,f,g}, Hermann Nabi^{a,c,d,h,i}, Julie Lemieux^{c,f}, Louise Provencher^{c,f}, Sophie Lauzier^{a,b,d,f,*}

Specific to cancer pain

A community pharmacist medicines optimisation service for patients with <u>advanced cancer pain</u>: a proof of concept study

Zoe Edwards¹ · Michael I. Bennett² · Alison Blenkinsopp¹

- 1. Mokbel et al. Anticancer Res. 2022;42(2):661-666
- 2. Labonté et al. Res Social Adm Pharm. 2020;16(12):1724-1736
- 3. Poole et al. Psychooncology. 2019;28(3):593-599
- 4. Lemanska et al. BMJ Open. 2019;9(6):e025114
- 5. Edwards et al. Int J Clin Pharm. 2019;41(3):700-710

Specific to lifestyle modification


Creating a teachable moment in community pharmacy for men with prostate cancer: A qualitative study of <u>lifestyle changes</u>

Karen Poole¹ ⁽ⁱ⁾ | Jane Ogden² | Sophie Gasson¹ | Agnieszka Lemanska¹ | Fiona Archer¹ | Bruce Griffin³ | John Saxton⁴ | Karen Lyons⁵ | Sara Faithfull¹

BMJ Open Community pharmacy <u>lifestyle</u> intervention to increase physical activity and improve cardiovascular health of men with prostate cancer: a phase II feasibility study

Agnieszka Lemanska,^{© 1} Karen Poole,¹ Bruce A Griffin,² Ralph Manders,³ John M Saxton,⁴ Lauren Turner,⁵ Joe Wainwright,⁶ Sara Faithfull¹


- <u>Overall</u> impact remains unclear
- Evaluation of care *in silo* <u>fragments</u> care conceptualization
- Overlooked importance of <u>team-based</u> care approach



Care model delivery is a <u>complex</u> intervention

RESEA	RCH	Intervention (E.g., new diabetic drug)	<u>Complex</u> intervention (E.g., care model delivery)
Mechanism of action		Biological pathways at molecular level	Theories, logic and systems thinking
Intervention characteristics	Intervention components	Active ingredient(s), usually independent	Multiple and interacting workflow changes, implementation strategies
	Flexibility	Strict adherence to protocol	Adaptable and pragmatic
	Level	Patient	Patient, organization/ institution, health system
Evaluating intervention	Study environment	Highly controlled	Real-world, context-sensitive
	Study endpoints	Efficacy	Effectiveness, implementation outcomes

Framework for health service development & research



Step 0:

Before embarking...

- Know your <u>context</u> barriers and facilitators?
- Assemble a committed <u>multidisciplinary</u> core workgroup – we cannot succeed alone!
- Identify and engage your key <u>stakeholders</u> they are important to ensure sustainability/ funding of your service!
- Source of preliminary funding grants, quality improvement funds, etc...






CASE STUDY: Developing and piloting a shared care model for Singapore breast cancer survivors

Getting to know the Singapore context

- High income Southeast Asian country
- Multi-ethnic and multilingual population
- Universal health coverage with a **co-payment** system
- Adopts the **<u>oncologist-led model</u>** for cancer survivorship

11077

Applying the framework for health service development & research



Step 1: The need for alternative care models

Cancer Supportive and Survivorship Care in Singapore: Current Challenges and Future Outlook

CURRENT CHALLENGES IN SINGAPORE'S SUPPORTIVE AND SURVIVORSHIP CARE LANDSCAPE

Health Care System

In Singapore, the majority of survivors of cancer consult their oncologists, who may be based at various cancer centers, for their supportive and survivorship care needs, with cancer surveillance being the primary focus of survivorship care. With the increasing cancer incidence and survival rates, the existing infrastructure in Singapore cannot meet the increasing demand for cancer supportive and survivorship care services in a sustainable manner. The current oncologist-centric survivorship landscape is in stark contrast with survivorship care models in the developed countries of North America and Europe, where primary care providers are actively involved in a shared-care model of survivorship care delivery.⁹ Such a shared-care

Historically, cancer has always been a disease managed in tertiary health care settings in Singapore, and currently, there is a lack of training or robust professional development courses to allow primary health care providers to develop skill sets in cancer survivorship. Without the involvement of primary health care providers in cancer survivorship care, community care coordination for survivors of cancer, especially those with complex comorbidities, is lacking. In recent years, there have been increasing efforts to transition care from tertiary institutes to the community by empowering and engaging community-based family physicians; however, it must be emphasized that Singapore's initiative for one family physician for every Singaporean is still in the infancy stage.^{15,16}


Limitations of oncologist-led model

Patient-level: suboptimal community care coordination, comorbidity management

Health system level: unable to meet the demands of a growing cohort of cancer survivors sustainably

Initial momentum for service development and research

Step 2: Which model is suitable for Singapore?



4. Chan et al. J Glob Oncol. 2017;3(2):98-104

1.

2.

3.

Step 3: Scope of exploratory research



Knowledge gaps

- a. A poor understanding of current survivorship care practice as a **comparator**.
- b. Unclear cross-system applicability of implementation recommendations from Western health care systems.

Research question	(a) How well does survivorship care provision adhere to ASCO care guidelines?	(b) What strategies could guide implementation of shared care in Singapore?
Study design	Retrospective observational study	Qualitative studies
Participants	Breast cancer survivors	Breast cancer survivors, family physicians, community pharmacists
Data collection	Medical records review	In-depth interviews, focus group discussions
Outcomes	Surveillance, monitoring late effects, healthcare utilization, preventive care	Perspectives and attitudes towards shared care, perceived barriers and facilitators
Analysis	Descriptive statistics, regression	Deductive thematic analysis

Step 3a: How well does survivorship care provision adhere to **ASCO care guidelines?**

SUPPORTIVE CARE & SYMPTOM CONTROL

Adherence to Cancer Survivorship Care **Guidelines and Health Care Utilization Patterns Among Nonmetastatic Breast Cancer Survivors** in Singapore repor

✓ Adherent to annual surveillance mammogram

- ✓ Adherent to osteoporosis preventive care
- **X** Extensive utilization of oncologist services in survivorship

Yu Ke, BSc Pharm (Hon)¹; Chia Jie Tan, PhD¹; Hui Ling Angie Yeo, MSc¹; and Alexandre Chan, PharmD, MPH^{2,3}

TABLE 4. Oncology, Nononcology Primary Care Consultations, Emergency Department Visits, and Hospitalizations Over the Follow-Up Period

0-6 (N = 189)	6-12) (N = 189)	12-18) (N = 189)	28-24) (N = 189)	24-30 (N = 189)	30-36) (N = 189)	36-42) (N = 139)	42-48 (N = 112)	48-54 (N = 78)	54-60 (N = 47)	
6 (4-10)) 4 (3-5)	3 (2-4)	2 (1-4)	2 (2-4)	2 (1-3)	2 (1-4)	2 (1-3)	2 (1-3)	2 (1-3)	~4 oncologist consultations annually Guideline: every 6-12months
181	232	242	232	310	303	264	171	121	55	
79 (41.8)	84 (44.4)	86 (45.5)	82 (43.4)	101 (53.4)	93 (49.2)	81 (58.3)	58 (51.8)	46 (59.0)	26 (55.3)	Increased % of survivors utilizing community services
19 (10.1)) 17 (9.0)	16 (8.5)	13 (6.9)	15 (7.9)	15 (7.9)	9 (6.5)	15 (13.4)	6 (7.7)	1 (2.1)	
18 (9.5)	4 (2.1)	5 (2.7)	4 (2.1)	0 (0)	7 (3.7)	4 (2.9)	6 (5.4)	3 (3.9)	1 (2.1)	
range. dical, radiolo	logic, and si	urgical oncc	ologists.							Opportunities to engage and coordinate care across settings
1	(N = 189) 6 (4-10) 181 79 (41.8) 19 (10.1) 18 (9.5) range.	(N = 189) (N = 189) 6 (4-10) 4 (3-5) 181 232 79 (41.8) 84 (44.4) 19 (10.1) 17 (9.0) 18 (9.5) 4 (2.1) range.	(N = 189) (N = 189) (N = 189) 6 (4-10) 4 (3-5) 3 (2-4) 181 232 242 79 (41.8) 84 (44.4) 86 (45.5) 19 (10.1) 17 (9.0) 16 (8.5) 18 (9.5) 4 (2.1) 5 (2.7) range.	(N = 189) (N = 189) (N = 189) (N = 189) 6 (4-10) 4 (3-5) 3 (2-4) 2 (1-4) 181 232 242 232 79 (41.8) 84 (44.4) 86 (45.5) 82 (43.4) 19 (10.1) 17 (9.0) 16 (8.5) 13 (6.9) 18 (9.5) 4 (2.1) 5 (2.7) 4 (2.1)	(N = 189)(N = 189)(N = 189)(N = 189)(N = 189)6 (4-10)4 (3-5)3 (2-4)2 (1-4)2 (2-4)18123224223231079 (41.8)84 (44.4)86 (45.5)82 (43.4)101 (53.4)19 (10.1)17 (9.0)16 (8.5)13 (6.9)15 (7.9)18 (9.5)4 (2.1)5 (2.7)4 (2.1)0 (0)range.	(N = 189)(N = 189)(N = 189)(N = 189)(N = 189)(N = 189)6 (4-10)4 (3-5)3 (2-4)2 (1-4)2 (2-4)2 (1-3)18123224223231030379 (41.8)84 (44.4)86 (45.5)82 (43.4)101 (53.4)93 (49.2)19 (10.1)17 (9.0)16 (8.5)13 (6.9)15 (7.9)15 (7.9)18 (9.5)4 (2.1)5 (2.7)4 (2.1)0 (0)7 (3.7)range.	(N = 189)(N = 189)(N = 189)(N = 189)(N = 189)(N = 189)(N = 139)6 (4-10)4 (3-5)3 (2-4)2 (1-4)2 (2-4)2 (1-3)2 (1-4)18123224223231030326479 (41.8)84 (44.4)86 (45.5)82 (43.4)101 (53.4)93 (49.2)81 (58.3)19 (10.1)17 (9.0)16 (8.5)13 (6.9)15 (7.9)15 (7.9)9 (6.5)18 (9.5)4 (2.1)5 (2.7)4 (2.1)0 (0)7 (3.7)4 (2.9)range.	(N = 189)(N = 139)(N = 112)6 (4-10)4 (3-5)3 (2-4)2 (1-4)2 (2-4)2 (1-3)2 (1-4)2 (1-3)18123224223231030326417179 (41.8)84 (44.4)86 (45.5)82 (43.4)101 (53.4)93 (49.2)81 (58.3)58 (51.8)19 (10.1)17 (9.0)16 (8.5)13 (6.9)15 (7.9)15 (7.9)9 (6.5)15 (13.4)18 (9.5)4 (2.1)5 (2.7)4 (2.1)0 (0)7 (3.7)4 (2.9)6 (5.4)range.	(N = 189)(N = 189)(N = 189)(N = 189)(N = 189)(N = 189)(N = 139)(N = 112)(N = 78)6 (4-10)4 (3-5)3 (2-4)2 (1-4)2 (2-4)2 (1-3)2 (1-4)2 (1-3)2 (1-3)18123224223231030326417112179 (41.8)84 (44.4)86 (45.5)82 (43.4)101 (53.4)93 (49.2)81 (58.3)58 (51.8)46 (59.0)19 (10.1)17 (9.0)16 (8.5)13 (6.9)15 (7.9)15 (7.9)9 (6.5)15 (13.4)6 (7.7)18 (9.5)4 (2.1)5 (2.7)4 (2.1)0 (0)7 (3.7)4 (2.9)6 (5.4)3 (3.9)range.	(N = 189)(N = 139)(N = 112)(N = 78)(N = 47)6 (4-10)4 (3-5)3 (2-4)2 (1-4)2 (2-4)2 (1-3)2 (1-4)2 (1-3)2 (1-3)2 (1-3)2 (1-3)1812322422323103032641711215579 (41.8)84 (44.4)86 (45.5)82 (43.4)101 (53.4)93 (49.2)81 (58.3)58 (51.8)46 (59.0)26 (55.3)19 (10.1)17 (9.0)16 (8.5)13 (6.9)15 (7.9)15 (7.9)9 (6.5)15 (13.4)6 (7.7)1 (2.1)18 (9.5)4 (2.1)5 (2.7)4 (2.1)0 (0)7 (3.7)4 (2.9)6 (5.4)3 (3.9)1 (2.1)range.

Step 3b: What strategies could guide the development and implementation of shared care in Singapore?

Practitioners' perspectives on community-based breast cancer survivorship care in Singapore: A focus group study

Alexandre Chan PharmD, MPH, FCCP, BCPS, BCOP^{1,2,3} G | Guo Hui Ngai BSc (Pharm) (Hons)¹ Wing Lam Chung BSc (Pharm) (Hons)⁴ | Angie Yeo BSc (Hons), MSc¹ | Terence Ng BSc (Pharm) (Hons), PhD^{1,2} | Kiley Wei-Jen Loh MBBS (Melbourne), FRACP (Australia)⁵ | Mohamad Farid MBBS, M Med (Int Med), MRCP (UK)⁵ | Yoke Lim Soong MBBS, FFRRCSI, FRCR⁶* | Rc Roles and recommendations from primary care physicians towards managing low-risk breast cancer survivors in a shared-care model with specialists in Singapore—a qualitative study

Rose Wai-Yee Fok^{a,*}, Lian Leng Low^{b,c}, Hui Min Joanne Quah^{c,d}, Farhad Vasanwala^e, Sher Guan Low^f, Ling Ling Soh^f, Farid Mohamad^a,

dre Chan^{c,h,i} and

Need to capture perspectives from <u>diverse groups</u> and all <u>key stakeholders</u> (e.g., survivors, health care professionals, leadership)


Perceptions and Daniel of Controls Care in Asia: Perceptions From Asian Breast Cancer Survivors

Open Access

Implementing a community-based shared care breast cancer survivorship model in Singapore: a qualitative study among primary care practitioners

Yu Ke^{1†}[®], Rose Wai Yee Fok^{2†}, Yoke Lim Soong³[®], Kiley Wei-Jen Loh², Mohamad Farid², Lian Leng Low⁴[®], Joanne Hui Min Quah⁵[®], Farhad Fakhrudin Vasanwala⁶, Sher Guan Low⁷, Ling Ling Soh⁷, Ngiap-Chuan Tan⁵[®] and Alexandre Chan^{8,9*}[®]

- 1. Chan et al. J Glob Oncol. 2016;3(2):98-104
- 2. Chan et al. Health Soc Care Community. 2018;26(3):404-411
- 3. Fok et al. Fam Pract. 2020;37(4):547-553
- 4. Ke et al. **BMC Prim Care**. 2022;23(1):73



Step 3b: Useful analytical framework

Step 3b: Understanding implementation barriers

Outer setting

- Health policy favoring primary care-based models
- Funding mechanisms supporting alternative care models

Individual

- Confidence/ knowledge
- Perceived benefits, attitude
- Oecision-making style
- Attitudes of primary care

Inner setting

Supporting leadership

Available resources

IT support, data

communications

Relative priority

Readiness for change

sharing

Network/

 \bigcirc

 \bigcirc

 \bigcirc

Step 4 & 5: Develop & test survivorship care tools

Distress thermometer (screening)

To be completed before consultation with primary care provider

To identify active problems (physical, practical, emotional) systematically and facilitate consultations.

Survivorship care plan

Treatment summary, key care areas to focus on, communication

Facilitates information sharing, updates on care across care providers.

Core workgroup



Training toolkit & workflows


- Provided by specialists from cancer center
- Didactic e-learning lectures, case studies discussion, clinical attachments with oncologists

Reduce clinical practice variation, improve primary care providers' selfefficacy and confidence.



Before continuing...

- Could you explain your service/ new model to a lay person? – versus usual care
- Are you clear about how the proposed service/ new model will work? – a logic model will be useful!



Clear roles & responsibilities distribution

Components of survivorship	Responsibilities	Oncologist	Family physician	Community pharmacist
	Assessment and management of toxicities	\checkmark	\checkmark	\checkmark
	Management of comorbidities		\checkmark	\checkmark
Follow-up medical care	Caring for patient's psychosocial wellbeing (referral to psychosocial team)	\checkmark	\checkmark	\checkmark
cure	Prescription of anti-cancer drugs	\checkmark		
	Prescription of drugs for comorbidities		\checkmark	
	Rapid access to oncologist (due to new symptoms)		\checkmark	\checkmark
	Perform breast examination	\checkmark	\checkmark	
	Assessing the need & scheduling for mammogram	\checkmark		
Surveillance for new/ recurrent cancers	Ensuring patient has scheduled/ completed mammogram	\checkmark	\checkmark	\checkmark
	Monitor for signs and symptoms of cancer recurrence/ secondary cancers	\checkmark	\checkmark	\checkmark
Health promotion	Health promotion Health promotion		\checkmark	\checkmark
Care coordination	Development of survivorship care plan	\checkmark		
	Updating survivorship care plan	\checkmark	\checkmark	\checkmark

Drafting an initial research logic model

Determinants (CFIR)

Intervention characteristics

- Encouraging evidence from literature
- Trialable in small scale
- Moderate complexity: changing workflows, inter-setting

Outer setting

- Early adopters within same healthcare cluster/ prior experience
- Peer pressure exerted by other healthcare cluster
- Overarching Healthier SG initiative

Inner setting

- Positive tension for change (strain in tertiary setting)
- Cultural shifts required

Individual characteristics

- Unclear overall beliefs, knowledge, state of change among cancer survivors and HCPs
- Unclear if primary care providers are self-efficacious to manage cancer survivors

Strategies & Mechanisms

Support care providers

 Facilitate information relay through survivorship care plans
 Promote communication in care teams to ensure care coordination

Develop stakeholder interrelations

- Identify & prepare champions
- Promote network weaving Reinforce value, sustainability, communication

Train & educate stakeholders

- Develop & distribute educational materials
- Conduct educational outreach activity
 Improve self-efficacy, enhance readiness

Restructuring roles/ workflows

• Creation of new pathways Minimize complexity, reinforces efficiency while ensuring safety

Engaging end-users

Publicity, roadshows,

Enhance uptake and adherence

Outcomes

Implementation

- Reach
- Adoption & appropriateness
- Cost
- Feasibility
- Fidelity

Service

- Safety
- Timeliness
- Patient-centeredness
- Effectiveness

Survivor outcomes

- Satisfaction levels
- Self-efficacy levels
- Quality of life
- Symptom burden

- Combined synthesis of results from exploratory research & literature review
- A "<u>roadmap</u>" for subsequent implementation & evaluation – What worked? For whom it worked? How did it work?

Evaluating a shared care model for breast cancer survivors in Singapore: a pilot randomized controlled trial

- Primary objective: assess the <u>feasibility</u> and <u>acceptability</u> of a shared care model for breast cancer survivors in Singapore
- 2. Secondary objective: provide robust parameters estimation of clinical outcomes' standard deviations for sample calculation in the expanded trial





Design: pilot randomized controlled studyStudy period: Mar 2021 to Jul 2022Follow-up duration: every 3 months to 1 year



Participants: 1) <u>></u>21 years, 2) breast cancer, 3) <u>></u>3 years aft primary treatment, 4) ECOG 0-2, 5) **low-risk ascertained**, 6) understand English/ Chinese

•
•
<u> </u>

Data collection: 1) EORTC QLQ-C30 questionnaire, 2) Rotterdam Symptom Checklist, 3) satisfaction questionnaire


_	

Outcomes: 1) acceptability, 2) feasibility of model delivery, 3) preliminary estimates of effectiveness measures, 4) satisfaction



Data analysis: descriptive statistics

Shared care model is generally acceptable



Participant characteristics

Characteristic	Intervention (N = 33)	Control (N = 35)	Р
Age, mean <u>+</u> SD	61.0 ± 6.2	60.9 ± 7.1	0.943
Race , n (%)			0.504
Chinese	29 (87.9%)	31 (88.6%)	
Malay	1 (3.0%)	2 (5.7%)	
Indian	0 (0%)	1 (2.9%)	
Marital status, n (%)			0.492
Single/ divorced/ widowed	13 (39.4%)	11 (31.4%)	
Widowed	20 (60.6%)	24 (68.6%)	
Private insurance, n (%)	13 (39.4%)	14 (40.0%)	0.959
Stay alone, n (%)	6 (18.2%)	3 (8.6%)	0.242
Education , years, mean <u>+</u> SD	$\textbf{11.7} \pm \textbf{4.5}$	$\textbf{10.3} \pm \textbf{4.0}$	0.164
Employed, n (%)	23 (69.7%)	16 (45.7%)	0.046
Survivorship, >5 years, n (%)	30 (90.9%)	33 (94.3%)	0.594
Treatment received, n (%)			
Surgery	31 (93.9%)	33 (94.3%)	0.952
Radiotherapy	18 (54.6%)	15 (42.9%)	0.335
Chemotherapy	15 (45.5%)	23 (65.7%)	0.093
Endocrine therapy	18 (54.6%)	16 (45.7%)	0.467
Comorbidity status, n (%)			0.283
No chronic condition	10 (30.3%)	15 (42.9%)	
<u>></u> 1 chronic condition	23 (69.7%)	20 (57.1%)	

• ≥5) years old
------	-------------

- Received pre-university education on average
- >5 years after active treatment
- <u>></u>1 of the common chronic conditions

Shared care is feasible in mobilizing survivors to engage with primary care

Indicator	Outcome (N = 33)	Overall acceptability of 2 visits per
Number of polyclinic visits, median (range)	2 (0, 6)	year to family physicians
Number of pharmacy consults, n (%) 1-2 consults 3 consults	4 (12.1%) 29 (87.9%)	Telehealth could innovatively integrate community pharmacists into survivorship care provision

Behavioral intentions

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i
 ?

 i


 i

 i

Would you want to **continue participation** in this intervention?

Would you **recommend** this intervention to your family members and friends if they needed cancer-related care?

Care experience was positive across all care providers




Signals for positive benefits of shared care

Outcomes –	Raw se	core (SD)	Attributable difference	P value	
	Intervention	Control	(95% CI)		
Physical sympto	om distress levels				
Baseline	9.47 (10.75)	9.17 (9.11)	-		
3 months	6.32 (7.75)	7.25 (8.88)	-1.06 (-4.88, 2.76)	>0.999	
6 months	6.76 (6.99)	8.03 (9.81)	-0.98 (-4.88, 2.92)	>0.999	
9 months	6.79 (7.78)	6.32 (9.92)	-0.50 (-4.40, 3.40)	>0.999	
12 months	6.50 (7.02)	11.96 (12.50)	-5.13 (-9.08, -1.19)	0.005	

- The evaluated cohort was well, with high functioning and low distress.
- Shared care's positive effect on physical symptom distress may stem from active co-management of longterm treatment effects.


Improvement in self-efficacy from baseline



86% of participants agreed that they felt more confident in managing their health as compared to baseline.

Revisiting the framework for health service development & research

This pilot trial directly informs the design of an expanded trial and endpoint selection, including the positive trends observed for physical distress levels and self-efficacy.



Reviewing our learning objectives

1. Define cancer survivorship and the underlying principles

- Cancer survivorship is a comprehensive and holistic concept \mathbf{V}
- \checkmark Core components of cancer survivorship care

2. Discuss the roles community pharmacists can play in breast cancer survivorship

- \mathbf{V} Active surveillance, second cancer screening
- \checkmark Medication compliance, optimization
- \checkmark Informational support, lifestyle modification

Tap on existing strengths, upskill where necessary, grow in tandem with progress in profession



Reviewing our learning objectives

3. Describe strategies to optimize community pharmacists' role in a multidisciplinary care team for cancer survivors

- Clear roles & responsibility distribution \rightarrow avoid duplicity/ confusion $\mathbf{\nabla}$
- \checkmark Engage their perspectives on perceived barriers \rightarrow *recognize their voices*
- \checkmark Targeted training and workflow support \rightarrow *provide assurance and instill* confidence
- $\mathbf{\nabla}$ Survivorship care plan \rightarrow adequate information sharing and communication

4. Discuss the types of resources commonly used to guide the implementation of health services involving pharmacists

- \checkmark Framework for health service development & research
- \checkmark **RE-AIM framework**
- \checkmark Consolidated Framework for Implementation Research (CFIR)
- \checkmark Implementation research logic model





Take home messages

- New health services involving pharmacists will involve the health system and multiple disciplines – work collaboratively in your context
- **Consider available evidence for your context** *assess the need for additional preliminary studies*
- Plan thoroughly and be flexible *expect the unexpected*
- **Be familiar with available research support** *implementation scientists, statisticians, epidemiologists...*
- Transforming both survivors' and community pharmacists' mentality of cancer survivorship as a <u>specialized care area</u> – work-in-progress

Thank you!